title: ACTH reduces the rise in ApoB-48 levels after fat intake.
abstract: It has been repeatedly demonstrated that ACTH administration lowers plasma lipid concentrations in man. The present study was designed to test the hypothesis, based on observations of decreased apolipoprotein B (ApoB) synthesis and secretion in vitro, that ACTH administration inhibits the postprandial output of ApoB in man. Therefore, we studied the response to a fat-rich meal supplemented with Vitamin A in eight healthy volunteers, who underwent this test without premedication, after 4 days administration of ACTH, and after 4 days administration of a glucocorticoid (betamethasone). As expected, fasting plasma levels of low-density lipoproteins (LDL)-cholesterol (-25%) and ApoB (-17%) decreased after ACTH, but not after betamethasone administration. Also, the elevation of plasma ApoB-48 in response to fat intake (to twice the basal levels) was markedly reduced after ACTH administration. However, the postprandial rise in plasma triglycerides and retinyl palmitate was unimpaired, suggesting that ACTH administration induced the secretion of fewer but larger chylomicrons. The effect of betamethasone on the postprandial response was similar but less pronounced. This study confirms earlier reports on the lipid-lowering effects of ACTH and supports our theory, based on in vitro studies, that the lipid-lowering effects of ACTH administration in man involves an inhibition of ApoB production.
authors.affiliation: Division of Clinical Chemistry and Pharmacology, Department of Laboratory Medicine, ILM, Lunds University, S-221 85 Lund, Sweden.
authors.forename: Maria
authors.initials: M
authors.lastname: Skoog
authors.forename: Ning
authors.initials: N
authors.lastname: Xu
authors.forename: Maria
authors.initials: M
authors.lastname: Berggren-Söderlund
authors.forename: Julie A
authors.initials: JA
authors.lastname: Lovegrove
authors.forename: Peter
authors.initials: P
authors.lastname: Nilsson-Ehle
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000008:administration & dosage / Q000502:physiology*; D000328:Adult; D053283:Apolipoprotein B-48 / Q000097:blood*; D001623:Betamethasone / Q000008:administration & dosage; D001786:Blood Glucose / Q000187:drug effects; D008078:Cholesterol, LDL / Q000097:blood; D002914:Chylomicrons / Q000378:metabolism; D004041:Dietary Fats / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005215:Fasting / Q000097:blood; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D050356:Lipid Metabolism / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D019518:Postprandial Period; D012016:Reference Values; D013997:Time Factors
chemical_list: D053283:Apolipoprotein B-48; D001786:Blood Glucose; D008078:Cholesterol, LDL; D002914:Chylomicrons; D004041:Dietary Fats; D005938:Glucocorticoids; D000324:Adrenocorticotropic Hormone; D001623:Betamethasone; D006854:Hydrocortisone